SQZ Biotech Overview
- Year Founded
-
2013
- Status
-
Acquired/Merged
- Employees
-
53
- Latest Deal Type
-
M&A
- Investors
-
4
SQZ Biotech General Information
Description
SQZ Biotechnologies Co is a clinical-stage biotechnology company developing transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Using its proprietary technology, SQZ has the ability to deliver multiple materials into many patient cell types to engineer what it believes to be an unprecedented range of potential therapeutics for a range of diseases. The company has the potential to create well-tolerated cell therapies that can provide therapeutic benefit for patients and potentially improve the patient experience over existing cell therapy approaches, with accelerated production timelines under 24 hours and the elimination of preconditioning and lengthy hospital stays.
Contact Information
Website
www.sqzbiotech.comCorporate Office
- 200 Arsenal Yards Boulevard
- Watertown, MA 02472
- United States
Corporate Office
- 200 Arsenal Yards Boulevard
- Watertown, MA 02472
- United States
SQZ Biotech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 13. Merger/Acquisition | 04-Mar-2024 | Completed | Generating Revenue/Not Profitable | |||
| 12. 2PO | 12-Feb-2021 | Completed | Generating Revenue | |||
| 11. IPO | 30-Oct-2020 | Completed | Generating Revenue | |||
| 10. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 9. Later Stage VC (Series D) | 18-May-2020 | Completed | Generating Revenue | |||
| 8. Later Stage VC | 18-Dec-2019 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series C) | 14-Aug-2018 | Completed | Generating Revenue | |||
| 6. Early Stage VC (Series B) | 01-Dec-2016 | Completed | Generating Revenue | |||
| 5. Grant | 01-Jan-2016 | $3.82M | $6.38M | Completed | Startup | |
| 4. Early Stage VC (Series A) | 28-Jul-2015 | $5.08M | $6.38M | Completed | Startup |
SQZ Biotech Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C | ||||||||
| Series B | ||||||||
| Series A | 1,490,035 | $0.001000 | 6% | $3.41 | $3.41 | 1x | $3.41 | 6.92% |
| Seed | 350,858 | $0.001000 | $2.85 | $2.85 | 1x | $2.85 | 1.63% |
SQZ Biotech Comparisons
Industry
Financing
Details
SQZ Biotech Competitors (11)
One of SQZ Biotech’s 11 competitors is Apellis Pharmaceuticals, a Formerly VC-backed company based in Waltham, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals | Formerly VC-backed | Waltham, MA | ||||
| CaroGen | Venture Capital-Backed | Farmington, CT | ||||
| Alvotech | Formerly PE-Backed | Reykjavik, Iceland | ||||
| Meditope Biosciences | Venture Capital-Backed | Pasadena, CA | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA |
SQZ Biotech Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
SQZ Biotech Patents
SQZ Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4377447-A1 | Methods to generate enhanced tumor infiltrating lymphocytes through microfluidic delivery | Pending | 29-Jul-2021 | ||
| EP-4337769-A1 | Methods for delivering genome editing molecules to the nucleus or cytosol of a cell and uses thereof | Pending | 10-May-2021 | ||
| EP-4314239-A1 | Reprogramming of cells and uses thereof | Pending | 02-Apr-2021 | ||
| EP-4271793-A1 | Microfluidic chip having increased throughput for use in a system for delivery of a payload into a cell | Pending | 29-Dec-2020 | ||
| EP-4271711-A1 | Methods for treating cancers with modified pbmcs | Pending | 29-Dec-2020 | A61K39/395 |
SQZ Biotech Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
SQZ Biotech Former Investors (24)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alumni Ventures | Venture Capital | Minority | ||
| Ascent Venture Partners | Venture Capital | Minority | ||
| Bob Rintel | Angel (individual) | Minority | ||
| Bridger Healthcare Partners | Venture Capital | Minority | ||
| C2I Accelerator | Accelerator/Incubator |
SQZ Biotech ESG
Risk Overview
Risk Rating
Updated October, 13, 2022
29.58 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,912
Rank
Percentile
Pharmaceuticals
Industry
of 965
Rank
Percentile
Biotechnology
Subindustry
of 443
Rank
Percentile
SQZ Biotech FAQs
-
When was SQZ Biotech founded?
SQZ Biotech was founded in 2013.
-
Where is SQZ Biotech headquartered?
SQZ Biotech is headquartered in Watertown, MA.
-
What is the size of SQZ Biotech?
SQZ Biotech has 53 total employees.
-
What industry is SQZ Biotech in?
SQZ Biotech’s primary industry is Drug Delivery.
-
Is SQZ Biotech a private or public company?
SQZ Biotech is a Private company.
-
What is SQZ Biotech’s current revenue?
The current revenue for SQZ Biotech is .
-
How much funding has SQZ Biotech raised over time?
SQZ Biotech has raised $298M.
-
Who are SQZ Biotech’s investors?
Alumni Ventures, Ascent Venture Partners, Bob Rintel, Bridger Healthcare Partners, and C2I Accelerator are 5 of 24 investors who have invested in SQZ Biotech.
-
Who are SQZ Biotech’s competitors?
Apellis Pharmaceuticals, CaroGen, Alvotech, Meditope Biosciences, and CytomX Therapeutics are some of the 11 competitors of SQZ Biotech.
-
When was SQZ Biotech acquired?
SQZ Biotech was acquired on 04-Mar-2024.
-
Who acquired SQZ Biotech?
SQZ Biotech was acquired by StemCell Technologies.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
